UK Court Invalidates AstraZeneca's Seroquel XR Patent

Law360, New York (March 22, 2012, 6:27 PM EDT) -- The U.K.'s High Court of Justice has invalidated an AstraZeneca AB patent for the extended release version of the company's anti-psychotic drug Seroquel XR, the drugmaker said Thursday.

The patent for the drug's formulation was challenged in British court by a host of generic-drug makers, including units of Teva Pharmaceutical Industries Ltd. and Sandoz Inc. as well as Accord Healthcare Ltd. and its parent Intas Pharmaceuticals Ltd.

The High Court of Justice's decision, which is the first such ruling finding the patent invalid in any court...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.